Emergency Department Access to Buprenorphine for Opioid Use Disorder
Notaufnahme-Zugang zu Buprenorphin bei Opioidkonsumstörung
JAMA Network Open · 29.01.2024 · 7 (1) · e2353771
DOI: 10.1001/jamanetworkopen.2023.53771 ↗Auf einen Blick
In 7 kalifornischen Notaufnahmen war Buprenorphin mit höherer Behandlungsbindung nach 30 Tagen verbunden. 49,7 % mit Behandlung versus 22,7 % ohne Behandlung blieben engagiert.
Fragestellung
Ist Buprenorphin in der Notaufnahme mit einer besseren Behandlungsbindung 1 Monat später bei OUD verbunden?
Methode
Multizentrische Kohortenstudie in 7 kalifornischen EDs; Erwachsene mit OUD zwischen 1. April 2021 und 30. Juni 2022; Auswertung mit hierarchischen generalisierten linearen Modellen.
Ergebnisse
464 Patient:innen mit OUD. 398 erhielten Buprenorphin; 198 (49,7 %) blieben nach 30 Tagen in Behandlung, versus 15 (22,7 %) ohne Buprenorphin. Adjusted risk ratio 1,97 (95 %-KI 1,27–3,07).
Schlussfolgerung der Autor:innen
Die Autoren:innen schlussfolgern, dass Buprenorphin bei Patient:innen mit OUD in EDs mit niedrigschwelligem Zugang mit einer deutlich höheren Wahrscheinlichkeit einer Nachbehandlung nach 1 Monat verbunden war.
Kernaussagen
- 49,7 % vs. 22,7 % Behandlungsbindung nach 30 Tagen
- Adjusted risk ratio 1,97 (95 %-KI 1,27–3,07)
- Multizentrische Kohortenstudie in 7 kalifornischen EDs
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 29.01.2024. Verfasst von Andrew A Herring und 10 weiteren Autor:innen. Beteiligte Einrichtung: Bridge, Public Health Institute, Oakland, California. Hauptthemen laut MEDLINE: Ethnicity, Buprenorphine. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Although substantial evidence supports buprenorphine for treatment of opioid use disorder (OUD) in controlled trials, prospective study of patient outcomes in clinical implementation of emergency department (ED) buprenorphine treatment is lacking.
Objective
To examine the association between buprenorphine treatment in the ED and follow-up engagement in OUD treatment 1 month later. Design, Setting, and Participants This multisite cohort study was conducted in 7 California EDs participating in a statewide implementation project to improve access to buprenorphine treatment. The study population included ED patients aged at least 18 years identified with OUD between April 1, 2021, and June 30, 2022. Data analysis was performed in October 2023. Exposure All participants were offered buprenorphine treatment for OUD (either in ED administration, prescription, or both), the uptake of which was examined as the exposure of interest. Main Outcomes and Measures The primary outcome was engagement in OUD treatment 30 days after the ED visit, determined by patient report or clinical documentation. The association of ED buprenorphine treatment with subsequent OUD treatment engagement was estimated using hierarchical generalized linear models.
Results
This analysis included 464 ED patients with OUD. Their median age was 36.0 (IQR, 29.0-38.7) years, and most were men (343 [73.9%]). With regard to race and ethnicity, 64 patients (13.8%) self-identified as non-Hispanic Black, 183 (39.4%) as Hispanic, and 185 as non-Hispanic White (39.9%). Most patients (396 [85.3%]) had Medicaid insurance, and more than half (262 [57.8%]) had unstable housing. Self-reported fentanyl use (242 [52.2%]) and a comorbid mental health condition (328 [71.5%]) were common. Interest in buprenorphine treatment was high: 398 patients (85.8%) received buprenorphine treatment; 269 (58.0%) were administered buprenorphine in the ED and 339 (73.1%) were prescribed buprenorphine. With regard to OUD treatment engagement at 30 days after the ED visit, 198 participants (49.7%) who received ED buprenorphine treatment remained engaged compared with 15 participants (22.7%) who did not receive ED buprenorphine treatment. An association of ED buprenorphine treatment with subsequent OUD treatment engagement at 30 days was observed (adjusted risk ratio, 1.97 [95% CI, 1.27-3.07]). Conclusions and Relevance The findings of this cohort study suggest that among patients with OUD presenting to EDs implementing low-threshold access to medications for OUD, buprenorphine treatment was associated with a substantially higher likelihood of follow-up treatment engagement 1 month later. Future research should investigate techniques to optimize both the uptake and effectiveness of buprenorphine initiation in low-threshold settings such as the ED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bridge, Public Health Institute, Oakland, California.
- Department of Emergency Medicine, Highland General Hospital-Alameda Health System, Oakland, California.
- Department of Emergency Medicine, University of California, San Francisco.
- Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles.
- Department of Emergency Medicine, David Geffen School of Medicine, University of California, Los Angeles.
- Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles.
Förderung
- NIMH NIH HHS
Zitieren
APA
Herring, A. A., Rosen, A. D., Samuels, E. A., Lin, C., Speener, M., Kaleekal, J., Shoptaw, S. J., Moulin, A. K., Campbell, A., Anderson, E., & Kalmin, M. M. (2024). Emergency Department Access to Buprenorphine for Opioid Use Disorder. JAMA Network Open, 7(1), e2353771. https://doi.org/10.1001/jamanetworkopen.2023.53771
Vancouver
Herring AA, Rosen AD, Samuels EA, Lin C, Speener M, Kaleekal J, et al. Emergency Department Access to Buprenorphine for Opioid Use Disorder. JAMA Network Open. 2024;7(1):e2353771. doi:10.1001/jamanetworkopen.2023.53771
BibTeX
@article{Herring2024,
author = {Herring, Andrew A and Rosen, Allison D and Samuels, Elizabeth A and Lin, Chunqing and Speener, Melissa and Kaleekal, John and Shoptaw, Steven J and Moulin, Aimee K and Campbell, Arianna and Anderson, Erik and Kalmin, Mariah M},
title = {Emergency Department Access to Buprenorphine for Opioid Use Disorder},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {1},
pages = {e2353771},
doi = {10.1001/jamanetworkopen.2023.53771}
}
EUVIMED